Somewhat Favorable News Coverage Somewhat Unlikely to Impact Esperion Therapeutics (ESPR) Share Price

Media headlines about Esperion Therapeutics (NASDAQ:ESPR) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 44.7411475653894 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Esperion Therapeutics (NASDAQ ESPR) traded up $3.77 during trading on Thursday, hitting $73.76. The stock had a trading volume of 636,700 shares, compared to its average volume of 583,088. The stock has a market cap of $1,890.00, a P/E ratio of -10.75 and a beta of 2.64. Esperion Therapeutics has a 52 week low of $20.39 and a 52 week high of $82.18.

Several equities analysts recently weighed in on ESPR shares. Northland Securities reiterated a “buy” rating and set a $72.00 target price on shares of Esperion Therapeutics in a research report on Friday, November 10th. Bank of America upgraded Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 target price on the stock in a research report on Friday, January 5th. BidaskClub upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 16th. UBS Group set a $88.00 target price on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, Stifel Nicolaus set a $105.00 target price on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 15th. Six analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $77.23.

In related news, Director Nicole Vitullo sold 9,326 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total transaction of $502,205.10. Following the sale, the director now directly owns 2,472 shares in the company, valued at approximately $133,117.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 32.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Week Herald and is owned by of Week Herald. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://weekherald.com/2018/02/15/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-esperion-therapeutics-espr-share-price.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Insider Buying and Selling by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply